Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ANI Pharmaceuticals (ANIP)

ANI Pharmaceuticals expects Q2 ILUVIEN and YUTIQ revenue of $22.3 million; NEW DAY trial misses goal

Mixed Impact 4 of 5 earnings Written later

ANI Pharmaceuticals said it expects combined ILUVIEN and YUTIQ net revenues of $22.3 million for the quarter ended June 30, 2025. The figures are preliminary and unaudited, and the filing gives no prior-year comparison. The company also reported that the primary endpoint of its NEW DAY trial of ILUVIEN for diabetic macular edema was not met, though a secondary endpoint was met.

Key points

  • Preliminary, unaudited combined ILUVIEN and YUTIQ net revenues of $22.3 million for the three months ended June 30, 2025; results not yet reviewed by auditor EisnerAmper LLP
  • NEW DAY primary endpoint not met: 2.4 vs. 2.5 mean supplemental aflibercept injections (p=0.756)
  • Secondary endpoint met: mean time to first supplemental aflibercept injection of 185.4 days for ILUVIEN vs. 132.8 days for aflibercept (p<0.001)
  • Post-hoc analysis in a subset without major protocol deviations showed 1.8 vs. 2.5 injections (p=0.029); results presented July 23, 2025 at the ASRS meeting with a conference call at 8:30 am ET

The filing

CompanyANI Pharmaceuticals (ANIP)
Form8-K, current report
Filed with the SECJul 23, 2025, 6:53 AM ET
Accession number0001023024-25-000072

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:58 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 23, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.